Crossmark

High cure rates and tolerability of artesunate–amodiaquine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma, Tanzania

Crossref DOI link: https://doi.org/10.1186/s12936-019-2740-z

Published Online: 2019-03-25

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mandara, Celine I. https://orcid.org/0000-0003-4317-4425
Francis, Filbert

Chiduo, Mercy G.

Ngasala, Billy

Mandike, Renata

Mkude, Sigsbert

Chacky, Frank

Molteni, Fabrizio

Njau, Ritha

Mohamed, Ally

Warsame, Marian

Ishengoma, Deus S.
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03431714 at ClinicalTrials.gov

Documents that mention this clinical trial

High cure rates and tolerability of artesunate–amodiaquine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Kibaha and Kigoma, Tanzania
https://doi.org/10.1186/s12936-019-2740-z
Funding

Funding for this research was provided by:

Global Fund to Fight AIDS, Tuberculosis and Malaria
License Information

Text and Data Mining valid from 2019-03-25

Version of Record valid from 2019-03-25
More Information

Article History

Received: 4 December 2018

Accepted: 20 March 2019

First Online: 25 March 2019

Document is current

Any future updates will be listed below